SCHEMBL5147701

SCHEMBL5147701

CSc1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(O)cc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 13/20 0.71
PTGS1 P23219 8/20 0.71
CYP2C9 P11712 4/20 0.53
CYP3A4 P08684 2/20 0.53
TSHR P16473 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C19 P33261 1/20 0.53
THPO P40225 1/20 0.53
BLM P54132 1/20 0.53
PMP22 Q01453 1/20 0.53
HIF1A Q16665 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
HDAC3 O15379 2/20 0.52
HDAC4 P56524 2/20 0.52
HDAC1 Q13547 2/20 0.52
HDAC7 Q8WUI4 2/20 0.52
HDAC2 Q92769 2/20 0.52
HDAC10 Q969S8 2/20 0.52
HDAC11 Q96DB2 2/20 0.52
HDAC8 Q9BY41 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25150243 0.88 PTGS2 (0.72) PTGS2PTGS1CYP2C9CYP3A4TSHR
SCHEMBL9273738 0.88 PTGS2 (0.72) PTGS2PTGS1CYP2C9CYP3A4TSHR
SCHEMBL9208582 0.87 PTGS2 (0.74) PTGS2PTGS1CYP2C9CYP3A4TSHR
SCHEMBL4032238 0.87 PTGS1 (0.74) PTGS2PTGS1CYP2C9CYP3A4TSHR
SCHEMBL8642061 0.86 PTGS2 (0.67) PTGS2PTGS1CYP2C9CYP3A4TSHR
SCHEMBL8641532 0.85 PTGS2 (0.69) PTGS2PTGS1CYP2C9HDAC3HDAC4
SCHEMBL8638458 0.85 PTGS2 (0.65) PTGS2PTGS1CYP2C9CYP3A4TSHR
SCHEMBL7460234 0.85 PTGS2 (0.69) PTGS2PTGS1CYP2C9HDAC3HDAC4
SCHEMBL14533183 0.85 PTGS2 (0.70) PTGS2PTGS1CYP2C9CYP3A4TSHR
SCHEMBL9201352 0.85 PTGS2 (0.68) PTGS2PTGS1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567503-B1 PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS ASTELLAS PHARMA INC (JP) 2011-12-21 EP disclosed
US-20070112037-A1 Pyrazole Derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2007-05-17 US disclosed
US-7183306-B2 Pyrazole derivatives ASTELLAS PHARMA INC. (JP) 2007-02-27 US disclosed
EP-1567503-A1 PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-08-31 EP disclosed
US-20040116475-A1 Pyrazole derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-17 US disclosed
WO-2004050632-A1 PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112037-A1 Pyrazole Derivatives CYP11B2, CYP11B1, CYP3A43 PTGS2 1780/4885PTGS1 1105/4885CYP2C9 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.